Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Receivables - Net (2017 - 2025)

Historic Receivables - Net for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $33.6 million.

  • Puma Biotechnology's Receivables - Net fell 3941.66% to $33.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.6 million, marking a year-over-year decrease of 3941.66%. This contributed to the annual value of $32.0 million for FY2024, which is 3308.32% down from last year.
  • Puma Biotechnology's Receivables - Net amounted to $33.6 million in Q3 2025, which was down 3941.66% from $26.1 million recorded in Q2 2025.
  • Puma Biotechnology's Receivables - Net's 5-year high stood at $55.4 million during Q3 2024, with a 5-year trough of $23.8 million in Q3 2021.
  • Over the past 5 years, Puma Biotechnology's median Receivables - Net value was $30.5 million (recorded in 2021), while the average stood at $32.1 million.
  • Per our database at Business Quant, Puma Biotechnology's Receivables - Net surged by 8788.32% in 2024 and then plummeted by 3941.66% in 2025.
  • Over the past 5 years, Puma Biotechnology's Receivables - Net (Quarter) stood at $32.5 million in 2021, then rose by 24.05% to $40.4 million in 2022, then grew by 18.56% to $47.8 million in 2023, then plummeted by 33.08% to $32.0 million in 2024, then grew by 4.85% to $33.6 million in 2025.
  • Its Receivables - Net was $33.6 million in Q3 2025, compared to $26.1 million in Q2 2025 and $25.2 million in Q1 2025.